CTLA4 and hepatocellular carcinoma: The use of tremelimumab (anti-CTLA-4) in combination with durvalumab (anti-PDL1) was studied in an open-label, phase 3 trial that investigated OS in patients randomly assigned to receive tremelimumab plus durvalumab or durvalumab or sorafenib in those with unresectable HCC.